PetVivo Holdings, Inc. has announced a significant equity financing initiative, securing $1 million through a Subscription Agreement. This agreement involves the issuance of 1,250,000 shares of restricted common stock to an accredited investor. The company received an initial payment of $400,000 on March 13, 2026, with the remaining $600,000 expected by April 15, 2026. Additionally, the investor has the option to invest an additional $1.5 million for 1,875,000 shares under similar terms, anticipated to be completed by June 30, 2026. This financing is aimed at supporting the commercialization of PetVivo's lead product, Spryng™ with OsteoCushion™ Technology, as well as funding new product development and clinical trials. The offering is conducted under the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, indicating a strategic move to bolster the company's financial position while maintaining compliance with regulatory requirements. The shares issued will be classified as restricted securities, which may limit their immediate liquidity but provide a pathway for future growth and investment opportunities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.